Søgning på udtrykket 'hepatitis' giver 118 resultater
Dokumenter [17]
Sider [4]
Kalender [55]
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [+20]
Dokumenter [17]
National guideline udarbejdet af en arbejdsgruppe nedsat af medlemmer fra Dansk Selskab for Infektionsmedicin og medlemmer fra Dansk Selskab for Gastroenterologi og Hepatologi.
National guideline udarbejdet af en arbejdsgruppe nedsat af medlemmer fra Dansk Selskab for Infektionsmedicin og medlemmer fra Dansk Selskab for Gastroenterologi og Hepatologi.
Omhandler biologiske og målrettede syntetiske lægemidler (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner.
Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Se
Diagnostik, behandling og forebyggelse af infektion med hepatitis A virus (HAV)
Forfattere: Jan Gerstoft, Nina Weis, Terese L. Katzenstein (Dansk Selskab for Infektionsmedicin), Anders Nyboe Andersen og Jens Fedder (Dansk Fertilitetsselskab).
Udarbejdet af en arbejdsgrupper bestående af medlemmer fra Dansk Selskab for Infektionsmedicin og Dansk Transplantationsselskab
Revideret september 2020. Arbejdsgruppen bestod af Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis
Bl.a. om HIV, hepatitis, resistente bakterier og immundefekt
Bl.a. om HIV, hepatitis, influenza og CNS infektioner
Bl.a. om HIV, hepatitis, cystisk fibrose og nye guidelines
Bl.a. om sygdom efter udlandsrejse, resistens og kroniske virale infektioner
Bilag til Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)
Sider [4]
Krogh-Madsen, Toke Barfod, Ulla Balslev, Hanne Arildsen, Lotte Ebdrup, Lars Toft Nielsen, Jon Holler
Gastrointestinale infektioner:
Karina Frahm Kirk (tovholder), Morten Helms, Merete Storgaard, Janne Fuglsang Hansen, Mike Zangenberg
Hepatitis:
Akut viral hepatitis:
Carsten Shade Larsen (tovholder) og Nina Weis.
Hepatitis A (2013),
Hepatitis elimination i Danmark:
Anne Øvrehus (tovholder), Peer Brehm Christensen, Nina Weis, Britta Tarp, Lone Mygind
National Strate
Se Kursus i CNS-infektioner 2024.
Sted.
Aalborg Universitets Hospital.
Delkursusledelse.
Jakob Bodilsen og Lars Omland.
Tidligere kurser.
11. og 12. april 2018.
9. og 10 september 2021.
Gastroenterologiske infektioner og kronisk hepatitis:
Dato for næste kursus
2026:
Sted
Odense Universitetshospital
Delkursusledelse
Lone Mygind, Micha Jepsen og Belinda Mössner
Tidligere kurser
4. og 5. december 2023
3. og 4. december 2020
HIV-infektion:
Næste kursus
Ef
ogiske oversigter (slides).
www.natap.org/. National AIDS Treatment Advocacy Project ? en New York State non-profit NGO ledet af Jules Levin (som selv lever med Hiv og hepatitis). God side, hvis man mangler slides/figurer/tabeller fra studier præsenteret på senest afholdte konferencer kommer ofte med referat (inklusive Jules Levins fortolkning ud fra et patient/aktivist perspektiv).
www.clinicaloptions.com/HIV.aspx. Et andet website for opdateringer og sammendrag af konferencer (slides).
Professor Henrik Nielsen kommenterer: I disse år sker et paradigmeskift i behandlingen af kronisk hepatitis C virus infektionen. Mange direkte virkende lægemidler er i afprøvning og med lovende resultater. Snart er interferon-baseret terapi ikke absolut nødvendig, mens oral terapi af kort varighed synes indenfor rækkevidde. Samtidigt er bivirkninger ved de nye lægemidler hidtil beskrevet som milde og sjældne. Kombination af sofosbuvir og ledipasvir i samme tablet bliver muligvis den første effektive
Professor Nina Weis kommenterer: Kronisk hepatitis B, forårsaget af forekomst af hepatitis B virus i blodet i > 6 måneder, kan klinisk manifestere sig fra asymptomatisk til fibrose, cirrose og hepatocellulært carcinom.
Trods forekomst af en effektiv vaccine i mere end 40 år, lever 296 millioner mennesker globalt med kronisk hepatitis B, heraf estimerede 14.500 i Danmark. Aktuelt er eneste behandlingstilbud (ofte livslang) antiviral terapi.
Denne artikel gennemgår naturhistorien, kendte og nye biomark
Kalender [55]
4. juni 2025, Barcelona, Spanien
4. juni 2025, Barcelona, Spanien
10. juni, Nielsine Nielsen Auditoriet, Panum, København
14. maj, Auditorium 3 og 4, Hvidovre Hospital
4. december 2023, Odense Universitetshospital
27. oktober 2023, Vandrehal lokale 3, Hvidovre Hospital
25. september 2023, Hvidovre Hospital
7. juni 2023, Rom, Italien
2. juni 2023, Auditorium 3 og 4, Hvidovre Hospital
26. oktober 2022, Auditorium 3 and 4, Hvidovre Hospital
17. juni 2022, Auditorium 3+4, Hvidovre Hospital
10. maj 2022, Auditorium 3+4, Hvidovre Hospital
3. december 2020, Hvidovre Hospital
28. oktober 2020, Paris, Frankrig
17. september 2020, Auditorium 3-4, Hvidovre Hospital
25. november 2019, Auditorium 3 og 4, Hvidovre Hospital
25. september 2019, London, England
11. september 2019, DGI-byen, København
21. juli 2019, Mexico City, Mexico
22. maj 2019, Rom, Italien
10. maj 2019, Auditorium 3 og 4, Hvidovre Hospital
15. februar 2019, Auditorium, University of Southern Denmark, J. B. Winsløws Vej 25, Odense
24. januar 2019, Aarhus Universitetshospital
28. november 2018, Hvidovre Hospital
30. maj 2018, Rom, Italien
4. maj 2018, Hindsgavl, Middelfart
9. april 2018, Amsterdam, Holland
27. februar 2018, Hvidovre Hospital
12. december 2017, Auditorium 3 og 4, Hvidovre Hospital
14. september 2017, IDA Mødecenter, Kalvebod Brygge 31, 1560 København V
30. maj 2017, Hvidovre Hospital
13. oktober 2016, Auditoriet, Syddansk Universitet
25. maj 2016, Rom, Italien
3. juni 2015, Barcelona, Spanien
24. marts 2015, Auditorium 3+4, Hvidovre Hospital
13. november 2014, Auditorium 3-4, Hvidovre Hospital
24. oktober 2014, Rigshospitalet
9. oktober 2014, Frankfurt, Tyskland
18. juli 2014, Aud. 3 og 4, Hvidovre Hospital, Kettegård Allé 30, 2650 Hvidovre
5. juli 2014, Sigtuna, Sverige
23. maj 2014, Aud. 3 og 4, Hvidovre Hospital, Kettegård Allé 30, 2650 Hvidovre
1. maj 2014, Berlin, Tyskland
26. marts 2014, Barcelona, Spanien
30. juni 2013, Kuala Lumpur, Malaysia
20. marts 2013, Rom, Italien
3. marts 2013, Atlanta, Georgia, USA
25. oktober 2012, Danmarks Medie- og Journalisthøjskole
18. oktober 2012, Berlin, Tyskland
7. november 2011, Auditorium 93, Rigshospitalet
24. maj 2011, Rigshospitalet, København
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Journal of Acquired Immune Deficiency Syndromes
27.10.2024
Background: . Little is known about the effect of HCV treatment on sexual risk behaviour among men who have sex with men (MSM) with HIV by treatment type (IFN-based vs DAA-based). Setting: . MSM with HIV and recently acquired HCV infection enrolled in the observational MOSAIC cohort. Methods: . Using data from 2009-2018, we evaluated risk behaviour through a validated HCV risk score (where ≥2 indicated high risk) and its individual risk behaviours. Levels of risk behaviour before, during and after trea
Microbiology and Molecular Biology Reviews
24.10.2024
Microbiology and Molecular Biology Reviews, Ahead of Print.
Journal of Medical Virology
22.10.2024
Journal of Medical Virology, Volume 96, Issue 10, October 2024.
PLoS One Infectious Diseases
19.10.2024
by Douwné L. Müller, Heather Stuckey, Eileen S. Flores, Li Wang, Thomas Godfrey, William A. Calo, Jessica Yingst . Background People with diabetes are at an increased risk of contracting the hepatitis B virus (HBV). However, hepatitis B (HepB) vaccination rates among adults with diabetes are low. Factors influencing HepB vaccination have not been adequately explored. Aims The study aims to identify and understand the barriers adults with diabetes have in receiving the recommended HepB vaccine from the p
PLoS One Infectious Diseases
18.10.2024
f A. Jereisat, Sara Abu-Mutaw, Haneen O. Abuhani, Raba’a F. Jarrar, Rayan M. Joudeh, Basmalah Al-Hawadi, Saif Alhawadi, Razan Qasim Al-oyoun, Hasan Nassr, Mohammad Al-Taher, Bassel Qiqieh, Layan Ismail, Haneen Al-Abdallat, Anas H. A. Abu-Humaidan . The Hepatitis B virus (HBV) is a prevalent blood-borne illness, posing a significant risk to hemodialysis patients particularly due to their potential immunosuppressed status. This study aimed to address HBV awareness among Jordanian hemodialysis patients, fil
Journal of Infectious Diseases
17.10.2024
Abstract . Background . Both HIV and hepatitis C virus (HCV) infection increase the risk of hepatic steatosis (HS), which in turn contributes to the severity and progression of liver disease. Direct acting antivirals (DAAs) can cure HCV but whether they reduce HS is unclear.Methods . HS was assessed using the controlled attenuation parameter (CAP) and the hepatic steatosis index (HSI) in participants coinfected with HIV-HCV from the Canadian Coinfection Cohort. Changes in HS, before, during and after succes
PLoS One Infectious Diseases
17.10.2024
by Macqueen Ngum Mbencho, Nourhane Hafza, Le Chi Cao, Victorine Ndiwago Mingo, Eric A. Achidi, Stephen Mbigha Ghogomu, Thirumalaisamy P. Velavan . Background Occult hepatitis B infection (OBI) is characterized by the presence of hepatitis B virus (HBV) DNA at low levels in serum (
BMJ Open
16.10.2024
. Introduction. Patient-reported measures are an invaluable resource for health systems to improve the quality of healthcare services. Patients with hepatitis C virus (HCV) are an under-represented group within the stream of literature on collecting and using the experiences and outcomes reported by patients to improve healthcare performance. This protocol outlines the methodology to implement a longitudinal survey in Tuscany, Italy, to systematically gather patient-reported outcome measures (PROMs) and pat
PLoS One Infectious Diseases
16.10.2024
by Florentin Pastor, Emilie Charles, Chiara Di Vona, Maëlys Chapelle, Michel Rivoire, Guillaume Passot, Benoit Chabot, Susana de la Luna, Julie Lucifora, David Durantel, Anna Salvetti . The genome of Hepatitis B virus (HBV) persists in infected hepatocytes as a nuclear episome (cccDNA) that is responsible for the transcription of viral genes and viral rebound, following antiviral treatment arrest in chronically infected patients. There is currently no clinically approved therapeutic strategy able to effic
BMC Infectious Diseases
13.10.2024
. Abstract. . Background. The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate. . . . Methods. We studied patients treated with NAs and PegIFN-2b at our institution from November 2
Journal of Infectious Diseases
10.10.2024
Abstract . Background . Hemodialysis (HD) patients represent a high-risk group for hepatitis B infection. It is crucial to administer hepatitis B vaccination and stimulate higher and more sustained levels of anti-HBs. Our aim is to enhance the immunogenicity and persistence by implementing high-dose and prolonged hepatitis B vaccine schedule regimen in HD patients.Methods . We conducted this multicenter, randomized, parallel-controlled trial between July 2020 and February 2023 at 11 hospitals in Shanxi prov
PLoS One Infectious Diseases
9.10.2024
by Mathias Mlewa, Helmut A. Nyawale, Shimba Henerico, Ivon Mangowi, Aminiel Robert Shangali, Anselmo Mathias Manisha, Felix Kisanga, Benson R. Kidenya, Hyasinta Jaka, Semvua B. Kilonzo, Mariam M. Mirambo, Stephen E. Mshana . Background Chronic hepatitis B virus (HBV) infection is still a major public health problem. In response to the World Health Organization (WHO), Tanzania implemented immunization and treatment to achieve the eradication of HBV infection by 2030. To achieve this goal, frequent updates o
BMC Infectious Diseases
9.10.2024
. Abstract. . Background. Chronic hepatitis B virus (HBV) infection remains a serious health issue, and determining the optimal time for antiviral therapy is challenging. We aimed to assess liver histological changes in patients with HBeAg-positive chronic hepatitis B (CHB) and those with HBeAg-negative CHB who had persistently normal alanine aminotransferase and to determine the association between significant liver injury
Antimicrobial Agents And Chemotherapy
4.10.2024
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Journal of Medical Virology
4.10.2024
Journal of Medical Virology, Volume 96, Issue 10, October 2024.
BMC Infectious Diseases
28.09.2024
. Abstract. . Background. Hepatitis C virus (HCV) antibody self-testing (HCVST) may help expand screening access and support HCV elimination efforts. Despite potential benefits, HCVST is not currently implemented in Pakistan. This study aimed to assess the usability and acceptability of HCVST in a high HCV prevalence informal settlement in Karachi, Pakistan. . . .
BMC Infectious Diseases
27.09.2024
Virulence
25.09.2024
Volume 15, Issue 1, December 2024 .
PLoS One Infectious Diseases
24.09.2024
C. Wilson, Willi McFarland . Background Transgender women (hereafter “trans women”) face social marginalization, stigma, and discrimination and experience a high burden of HIV. More recently, trans women have been identified as having a high risk for hepatitis C (HCV) infection. The interaction between these two diseases and the risks for HIV/HCV co-infection among trans women are understudied. Objective To characterize epidemiological, behavioral, and socio-structural interactions between HIV and HCV
BMC Infectious Diseases
18.09.2024
. Abstract. . Background. Prior research predominantly examined the association between HIV-positive men who have sex with men (MSM) or those using injection drugs and hepatitis C virus (HCV) infection. However, limited attention has been given to understanding the association among HIV-negative MSM who do not inject drugs. This gap leaves apportion of the population unexamined, potentially overlooking important factor that
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Eurosurveillance latest updates
26.10.2024
. Background. Hepatitis E, a viral hepatitis caused mainly by the ingestion of raw or undercooked food, is not a notifiable disease in Spain. . . Aim. To analyse the temporal trends, epidemiological characteristics and factors associated with severe disease from hepatitis E hospitalisations in Spain from 1997 to 2019. . . Methods. Hospitalisation records were obtained from the Spanish National Hospital Discharge Database. Temporal trends and seasonality were analysed by Poisson regression in years 199
Medscape Infectious Diseases
28.09.2024
The study highlighted that 57.7% of neonates in the case group had a diagnosis of neonatal abstinence syndrome compared to 10.0% in the control group. . Medscape Medical News
Medscape Infectious Diseases
31.08.2024
The rules about whom to screen and vaccinate for hepatitis B are now more clinician-friendly. . The Curbsiders
Morbidity and Mortality Weekly Report (MMWR)
2.08.2024
This report describes progress toward eliminating hepatitis B and C in the country of Georgia.
Medscape Infectious Diseases
29.07.2024
This requires sensitivity to stigmas and awareness of hepatitis B and C prevalence in local communities. . Medscape Medical News
Eurosurveillance latest updates
26.07.2024
. Introduction. Obtaining epidemiological data on chronic hepatitis C virus (HCV) infection is essential to monitor progress towards the hepatitis C elimination targets. . . Aim. We aimed to estimate the prevalence of chronic HCV and the seroprevalence of HCV in the adult general population in Estonia. . . Methods. This cross-sectional study, conducted between 12 July and 6 December 2022, included anonymised residual sera collected prospectively from patients 18 years and older visiting a general prac
Eurosurveillance latest updates
26.07.2024
. Introduction. A national study from 2006 to 2008 showed a high antibody prevalence of 3.2% against hepatitis C virus (HCV) in Romania, but more recent epidemiological data on hepatitis C prevalence are lacking. . . Aim. We aimed to estimate the current prevalence of HCV antibodies (anti-HCV) and chronic HCV infection in the general adult population in Romania, as a crucial element in monitoring progress towards eliminating hepatitis C. . . Methods. We used anonymised leftover sera from a SARS-CoV-2
Eurosurveillance latest updates
26.07.2024
.
Morbidity and Mortality Weekly Report (MMWR)
25.07.2024
This report describes vaccination efforts to eliminate mother-to-child hepatitis B.
Eurosurveillance latest updates
20.07.2024
. Background. People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. . . Aim. To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. . . Methods. We conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, fo
Eurosurveillance latest updates
20.07.2024
. Background. Active follow-up of chronic hepatitis C notifications to promote linkage to care is a promising strategy to support elimination. . . Aim. This pilot study in Victoria, Australia, explored if the Department of Health could follow-up on hepatitis C cases through their diagnosing clinicians, to assess and support linkage to care and complete data missing from the notification. . . Methods. For notifications received between 1 September 2021 and 31 March 2022 of unspecified hepatitis C cases
Eurosurveillance latest updates
14.06.2024
. Background. Awareness of transfusion-transmitted hepatitis E raised in recent years led to the mandatory testing of blood donations in some European countries for hepatitis E virus (HEV) RNA. However, little is known about the epidemiology of HEV infections. . . Aim. To and describe and analyse the epidemiology of HEV infections in blood donors in Germany. . . Methods. Data from routine testing of therapeutic blood products donated between January 2015 and December 2022 at the Uni.Blutspendedienst O
Morbidity and Mortality Weekly Report (MMWR)
31.05.2024
This report describes hepatitis C viral clearance proportions among people with hepatitis C by state.
Eurosurveillance latest updates
26.05.2024
An outbreak of hepatitis A is ongoing in Portugal, with 71 confirmed cases from 7 October 2023 to 24 April 2024. Most cases are male, aged 18–44 years, with many identifying as men who have sex with men (MSM) and reported as suspected sexual transmission. Phylogenetic analysis identified the subgenotype IA, VRD 521–2016 strain, last observed in an MSM-associated multi-country outbreak in 2016 to 2018. We wish to alert colleagues in other countries to investigate potential similar spread. .
Eurosurveillance latest updates
24.05.2024
An outbreak of hepatitis A is ongoing in Portugal, with 71 confirmed cases from 7 October 2023 to 24 April 2024. Most cases are male, aged 18–44 years, with many identifying as men who have sex with men (MSM) and reported as suspected sexual transmission. Phylogenetic analysis identified the subgenotype IA, VRD 521–2016 strain, last observed in an MSM-associated multi-country outbreak in 2016 to 2018. We wish to alert colleagues in other countries to investigate potential similar spread. .
Medscape Infectious Diseases
15.05.2024
The U.S. drug regulator has declined to approve expanded use of Dynavax Technologies' hepatitis B vaccine in a section of patients, citing insufficient data over destruction. . Reuters Health Information
Medscape Infectious Diseases
24.04.2024
Although annual incidence decreased from 2.5 million in 2019 to 2.2 million in 2022, the WHO considers it to be high. . Medscape Medical News
Medscape Infectious Diseases
8.04.2024
While the hepatitis E virus causes tens of thousands of deaths each year, data suggest that a vaccine approved in China has long-term efficacy. . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
16.02.2024
This report describes Correctional Health Services and LA County Jail's response to a confirmed case of Hepatitis A in a person who is incarcerated.
Medscape Infectious Diseases
1.12.2023
At least 450 patients at Mass General Brigham, Salem Hospital, near Boston are at risk of HIV and hepatitis infection, according to a lawsuit claiming negligent intravenous medication administration. . Medscape Medical News